Lectin PCL inhibits the Warburg effect of PC3 cells by combining with EGFR and inhibiting HK2

Zhang,Hong; Du,Xia; Sun,Ting-Ting; Wang,Chun-Liu; Li,Ye; Wu,Shou-Zhen

doi:10.3892/or.2017.5367

Lectin PCL inhibits the Warburg effect of PC3 cells by combining with EGFR and inhibiting HK2

Authors:
- Hong Zhang
- Xia Du
- Ting-Ting Sun
- Chun-Liu Wang
- Ye Li
- Shou-Zhen Wu
View Affiliations

Affiliations: Institute of Traditional Chinese Medicine, Shaanxi Academy of Traditional Chinese Medicine, Xi'an, Shaanxi 710003, P.R. China, Xi'an Children's Hospital, Xi'an, Shaanxi 710003, P.R. China
Published online on: January 16, 2017 https://doi.org/10.3892/or.2017.5367
Pages: 1765-1771

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Prostatic carcinoma is the most aggressive tumor in adult men. Warburg effect is an important characteristic of tumor cell metabolism including prostate cancer cells, in which hexokinase 2 (HK2), a major rate-limiting enzyme involved in Warburg effect, is selectively upregulated. The lectin PCL is a mannose binding lectin which induces tumor cell apoptosis and autophagy. In the present study, we report that PCL could lower glucose consumption and lactate production, shift the Warburg effect by inhibiting the expression of HK2 in PC3 cells and the suppression of HK2 by siRNA reversed the effect of PCL on glucose consumption and lactate production. The expression of HK2 is closely related to epidermal growth factor receptor (EGFR) and downstream signaling pathway activation, therefore, we investigated the interaction of PCL with EGFR by western blot analysis and found that PCL could suppress the binding of epidermal growth factor (EGF) with EGFR and HK2 expression. Also, we explored the binding mechanism between the PCL and EGFR through molecular docking and molecular dynamics simulations and found that PCL bocked the active site of EGFR which is also the binding site of the nature ligand EGF, the resulting conformation has higher stability than EGF in complex with EGFR. The results indicated that PCL could competitively bind to EGFR binding pocket and then prevent EGF from binding to EGFR, blocking the autophosphorylation of the EGFR tyrosine kinase, after that the EGFR activation is inhibited. Collectively, our studies concluded that PCL inhibits tumor cell glycolysis by combining with EGFR and reducing HK2 expression.

View Figures

View References

1	Mahjoubi M, Azab M, Ghosn M, Theodore C and Droz JP: Phase II trial of ifosfamide in the treatment of metastatic hormone-refractory patients with prostatic cancer. Cancer Invest. 8:477–481. 1990. View Article : Google Scholar : PubMed/NCBI
2	Kroemer G and Pouyssegur J: Tumor cell metabolism: cancer ‘Achilles’ heel. Cancer Cell. 13:472–482. 2008. View Article : Google Scholar : PubMed/NCBI
3	Warburg O, Posener K and Negelein E: Ueber den stoffwechsel dercarcinomzelle. Biochem Z. 152:309–344. 1924.
4	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
5	Mayevsky A: Mitochondrial function and energy metabolism in cancer cells: past overview and future perspectives. Mitochondrion. 9:165–179. 2009. View Article : Google Scholar : PubMed/NCBI
6	Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
7	Jiang XZ, Yan LN, Sun GY, Zhao SY, Gu JM, Lei KJ, Zhu Y and Wang CS: Expression of hypoxia-inducible factor-1 alpha, hexokinase-II and lactate dehydrogenase-V in hepatocellular carcinoma and their biological significance. Chin J Cancer Prev Treat. 1:41–44. 2013.
8	Fan YX, Shi WM, Li J, Yin JL, Yang CH, Huang KL, Liu QZ, Li KB and Wu JZ: Relationship between fluorodeoxyglucose uptake and overexpression of glucose transport protein 1 and hexokinase-II in early-stage nasopharyngeal carcinoma. Chin J Nucl Medi. 30:166–169. 2010.
9	Herrala AM, Porvari KS, Kyllönen AP and Vihko PT: Comparison of human prostate specific glandular kallikrein 2 and prostate specific antigen gene expression in prostate with gene amplification and overexpression of prostate specific glandular kallikrein 2 in tumor tissue. Cancer. 92:2975–2984. 2001. View Article : Google Scholar : PubMed/NCBI
10	He HC, Bi XC, Zheng ZW, Dai QS, Han ZD, Liang YX, Ye YK, Zeng GH, Zhu G and Zhong WD: Real-time quantitative RT-PCR assessment of PIM-1 and HK2 mRNA expression in benign prostate hyper-plasia and prostate cancer. Med Oncol. 26:303–308. 2009. View Article : Google Scholar : PubMed/NCBI
11	Pedersen PL: Warburg, me and Hexokinase 2: Multiple discoveries of key molecular events underlying one of cancers most common phenotypes, the ‘Warburg effect’, i.e., elevated glycolysis in the presence of oxygen. J Bioenerg Biomember. 39:211–222. 2007. View Article : Google Scholar
12	Bhaskar PT and Hay N: The two TORCs and Akt. Dev Cell. 12:487–502. 2007. View Article : Google Scholar : PubMed/NCBI
13	Zhang ZT, Peng H, Li CY, Liu JJ, Zhou TT, Yan YF, Li Y and Bao JK: Polygonatum cyrtonema lectin induces murine fibrosarcoma L929 cell apoptosis via a caspasedependent pathway as compared to ophiopogon japonicus lectin. Phytomedicine. 18:25–31. 2010. View Article : Google Scholar : PubMed/NCBI
14	Liu B, Wu JM, Li J, Liu JJ, Li WW, Li CY, Xu HL and Bao JK: Polygonatum cyrtonema lectin induces murine fibrosarcoma L929 cell apoptosis and autophagy via blocking Ras-Raf and PI3K-Akt signaling pathways. Biochimie. 92:1934–1938. 2010. View Article : Google Scholar : PubMed/NCBI
15	Liu B, Cheng Y, Zhang B, Bian HJ and Bao JK: Polygonatum cyrtonema lectin induces apoptosis and autophagy in human melanoma A375 cells through a mitochondria-mediated ROS-p38-p53 pathway. Cancer Lett. 275:54–60. 2009. View Article : Google Scholar : PubMed/NCBI
16	Ferguson KM, Berger MB, Mendrola JM, Cho HS, Leahy DJ and Lemmon MA: EGF activates its receptor by removing interactions that auto-inhibit ectodomain dimerization. Mol Cell. 11:507–517. 2003. View Article : Google Scholar : PubMed/NCBI
17	Ding JJ, Bao JK, Zhu DY, Zhang Y and Wang DC: Crystal structures of a novel anti-HIV mannose-binding lectin from Polygonatum cyrtonema Hua with unique ligand-binding property and super-structure. J Struct Biol. 171:309–317. 2010. View Article : Google Scholar : PubMed/NCBI
18	Kozakov D, Beglov D, Bohnuud T, Mottarella SE, Xia B, Hall DR and Vajda S: How good is automated protein docking? Proteins. 81:2159–2166. 2013. View Article : Google Scholar : PubMed/NCBI
19	Kozakov D, Brenke R, Comeau SR and Vajda S: PIPER: An FFT-based protein docking program with pairwise potentials. Proteins. 65:392–406. 2006. View Article : Google Scholar : PubMed/NCBI
20	Comeau SR, Gatchell DW, Vajda S and Camacho CJ: ClusPro: an automated docking and discrimination method for the prediction of protein complexes. Bioinformatics. 20:45–50. 2004. View Article : Google Scholar : PubMed/NCBI
21	Comeau SR, Gatchell DW, Vajda S and Camacho CJ: ClusPro: a fully automated algorithm for protein-protein docking. Nucl Acids Res. 32:W96–W99. 2004. View Article : Google Scholar : PubMed/NCBI
22	Bao JK, Zeng ZK and Zhou H: Purification and characterization of the polygonatum cyrtonema Hua. Lectin II. Chin Biochem J. 12:165–170. 1996.
23	Velpula KK, Bhasin A, Asuthkar S and Tsung AJ: Combined targeting of PDKi and EGFR triggers regression of glioblastoma by reversing the Warburg effect. Cancer Res. 73:7277–7289. 2013. View Article : Google Scholar : PubMed/NCBI
24	Toschi A, Lee E, Thompson S, Gadir N, Yellen P, drain C Michael, Ohh M and Foster DA: Phospholipase D-mTOR requirement for the Warburg effect in human cancer cells. Cancer Lett. 299:72–79. 2010. View Article : Google Scholar : PubMed/NCBI
25	Barducci A, Bussi G and Parrinello M: Well-tempered metadynamics: A smoothly converging and tunable free-energy method. Phys Rev Lett. 100:0206032008. View Article : Google Scholar : PubMed/NCBI
26	Ilott AJ, Palucha S, Hodgkinson P and Wilson MR: Well-tempered metadynamics as a tool for characterizing multi-component, crystalline molecular machines. J Phys Chem B. 117:12286–12295. 2013. View Article : Google Scholar : PubMed/NCBI
27	Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, Villa E, Chipot C, Skeel RD, Kalé L and Schulten K: Scalable molecular dynamics with NAMD. J Comput Chem. 26:1781–1802. 2005. View Article : Google Scholar : PubMed/NCBI
28	Bonomi M, Branduardi D, Bussi G, Camilloni C, Provasi D, Raiteri P, Donadio D, Marinelli F, Pietrucci F, Broglia RA and Parrinello M: Plumed: A portable plugin for free-energy calculations with molecular dynamics. Comput Phys Commun. 180:1961–1972. 2009. View Article : Google Scholar
29	Darden T, York D and Pedersen L: Particle mesh Ewald: An N•log(N) method for Ewald sums in large systems. J Chem Phys. 98:10089–10092. 1993. View Article : Google Scholar
30	Adelman SA and Doll JD: Generalized langevin equation approach for atom/solid-surface scattering: general formulation for classical scattering off harmonic solids. J Chem Phys. 64:2375–2388. 1976. View Article : Google Scholar
31	Davidchack RL, Handel R and Tretyakov MV: Langevin thermostat for rigid body dynamics. J Chem Phys. 130:2341012009. View Article : Google Scholar : PubMed/NCBI
32	Feller SE, Zhang Y, Pastor RW and Brooks BR: Constant pressure molecular dynamics simulation: the Langevin piston method. J Chem Phys. 103:4613–4621. 1995. View Article : Google Scholar
33	Cornell WD, Cleplak P and Bayly CI: A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. J Am Chem Soc. 117:5179–5197. 1995. View Article : Google Scholar
34	Liu B, Cheng Y, Bian HJ and Bao JK: Molecular mechanisms of Polygonatum cyrtonema lectin-induced apoptosis and autophagy in cancer cells. Autophagy. 5:253–255. 2009. View Article : Google Scholar : PubMed/NCBI
35	Kirkwood JG: Statistical mechanics of fluid mixtures. J Chem Phys. 3:300–313. 1935. View Article : Google Scholar
36	Mathupala SP, Ko YH and Pedersen PL: Hexokinase-2 bound to mitochondria: cancer's stygian link to the ‘Warburg Effect’ and a pivotal target for effective therapy. Semin Cancer Biol. 19:17–24. 2009. View Article : Google Scholar : PubMed/NCBI
37	Wang L, Xiong H, Wu F, Zhang Y, Wang J, Zhao L, Guo X, Chang LJ, Zhang Y, You MJ, et al: Hexokinase 2-mediated Warburg effect is required for PTEN- and p53-deficiency-driven prostate cancer growth. Cell Rep. 8:1461–1474. 2014. View Article : Google Scholar : PubMed/NCBI
38	Dong G, Mao Q, Xia W, Xu Y, Wang J, Xu L and Jiang F: PKM2 and cancer: The function of PKM2 beyond glycolysis. Oncol Lett. 11:1980–1986. 2016.PubMed/NCBI